Article info
PDFPostScript
Letter
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
- Correspondence to A Gils, Laboratory for Pharmaceutical Biology, Department of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Herestraat 49 box 824, Leuven 3000, Belgium; ann.gils{at}pharm.kuleuven.be
Citation
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
Publication history
- First published February 17, 2011.
Online issue publication
April 18, 2016
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.